CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingCRSP
Biotech & Genomic Medicine▲2impact 4
CRISPR Therapeutics reports $76 million in CASGEVY revenue and narrower Q2 net loss
CRISPR Therapeutics reported second quarter 2026 financial results, with CASGEVY revenue reaching $76 million, a 78% increase quarter-over-quarter and 151% year-over-year. The U.S. FDA recently approved CASGEVY for children as young as 2 years old with sickle cell disease or transfusion-dependent beta thalassemia, making it the first genetic therapy indicated for this age group and potentially expanding the eligible patient population by approximately 5,500. The company also initiated Phase 1 clinical trials for two in vivo gene editing candidates, CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. Net loss for the quarter narrowed to $91.2 million from $208.5 million a year earlier, while cash, cash equivalents, and marketable securities rose to $2.36 billion, boosted by $585.4 million in net proceeds from a convertible senior notes offering in March 2026.
CRISPR Therapeutics trades 78% below DCF fair value estimate of $221.98
CRISPR Therapeutics shares rebounded in the latest session but remain well below fair value according to a Simply Wall St discounted cash flow model. The model estimates a fair value of $221.98 per share, implying the stock is trading at about a 78.4% discount to that estimate at its recent close of $47.99. Analyst consensus targets sit far lower at $86.21, representing a roughly 20.4% discount from the current price. The company is currently reporting a net loss of $568.53 million against revenue of $4.10 million, highlighting its reliance on future commercialization of gene editing programs. The wide gap between the DCF estimate and analyst targets underscores how sensitive the valuation is to assumptions about future cash flows and commercialization timing.
Motley Fool Highlights Three Mid-Cap Growth Stocks With Massive Long-Term Potential
The Motley Fool identifies Archer Aviation, CRISPR Therapeutics, and e.l.f. Beauty as mid-cap growth stocks with significant long-term upside. Archer Aviation, with a market cap of roughly $3.6 billion, is developing electric vertical take-off and landing aircraft and recently unveiled new autonomous models for defense and commercial use, though its stock has fallen 38% this year. CRISPR Therapeutics, valued at around $4.5 billion, is rolling out its gene therapy Casgevy for sickle cell disease and beta thalassemia, priced at $2.2 million per one-time treatment, while posting a net loss of $123 million in the first quarter. e.l.f. Beauty, with a valuation of $4.9 billion, reported net sales of $1.6 billion and adjusted net income of $185.9 million in its latest fiscal year, but its stock has declined 30% over the past 12 months amid tariff concerns.
Cathie Wood's $362 Million CRISPR Therapeutics Bet Is Backed by Underrated CAR T-Cell Therapy Catalyst
Cathie Wood's Ark Investment Management holds nearly $362 million in CRISPR Therapeutics across its flagship Ark Innovation ETF and the Ark Genomic Revolution ETF. While the company is known for its FDA-approved gene-editing drug Casgevy, Wood's conviction may be driven by CRISPR's off-the-shelf CAR T-cell therapy program, which is advancing through clinical trials. Its lead candidate, zugocabtagene geleucel, is in phase 1 trials for lymphoma and autoimmune diseases, using donor cells rather than patient-specific samples to potentially reduce costs. The global CAR T-cell therapy market is projected to grow over 30% annually to exceed $60 billion by 2034, though CRISPR faces competition from Novartis, Bristol Myers Squibb, and Gilead Sciences.
CRISPR Therapeutics Valuation Seen as About Right After 61% Five-Year Decline
CRISPR Therapeutics stock has fallen roughly 61% over the past five years, and current valuation checks suggest the shares now sit closer to about right territory rather than looking clearly cheap or expensive. The company holds a strong cash position of around US$2.4 billion, which supports ongoing development of its gene editing pipeline, while emerging tools such as the experimental DNA shredder approach may increase uncertainty over which technologies will capture value. CRISPR Therapeutics currently trades at a price-to-book ratio of about 2.6 times, almost identical to the biotech industry average of roughly 2.6 times, and well below many peer biotechs that sit around 9.5 times book. A mixed valuation picture, with three out of six checks screening as attractive, suggests the stock is not an obvious bargain but also not priced at an extreme premium. The key question is whether the company can convert its pipeline into commercially meaningful products before sentiment or competing gene editing approaches reset what investors are willing to pay.
Analysts project $1.10 EPS loss for CRISPR Therapeutics amid sharp revenue growth
Analysts project a US$1.10 per-share loss for CRISPR Therapeutics alongside very large year-over-year revenue growth in its upcoming results, sharpening focus on the company's gene-editing commercialisation progress. The combination of improving earnings expectations and strong sales momentum has intensified scrutiny on how CRISPR is advancing its pipeline toward sustainable revenue. Despite the anticipated improvement, the market's muted reaction highlights persistent concerns over ongoing losses and limited current revenue. Short-term catalysts remain tied to clinical progress and early commercial traction as the company transitions from a largely loss-making R&D story.
CRISPR Therapeutics and Viking Therapeutics are two beaten-down biotech stocks with significant upside potential, according to an analysis. CRISPR Therapeutics, known for the first approved CRISPR-based gene-editing therapy Casgevy, has seen its stock decline since 2021 due to profit-taking, slow Casgevy revenue, and unprofitability, but upcoming clinical data readouts and Casgevy's blockbuster potential could drive a recovery. Viking Therapeutics, which surged on strong phase 2 results for its obesity drug VK2735, has since pulled back, yet its pipeline—including an oral VK2735 formulation, a phase 3-ready NASH candidate VK2809, and the orphan drug VK0214—positions it for substantial gains if clinical and regulatory milestones are met. Both companies carry typical biotech risks, but their innovative pipelines and market opportunities make them compelling for risk-tolerant investors.
CRISPR Therapeutics could be an attractive buy-and-hold option despite its recent underperformance and current lack of profitability. The biotech has multiple catalysts on the way, including results from an ongoing clinical trial of CTX310, an investigational one-time gene-editing treatment designed to permanently lower LDL cholesterol, expected in the second half of the year. Its approved therapy Casgevy, developed with Vertex Pharmaceuticals, recently received a label expansion from the U.S. Food and Drug Administration to include children as young as two, adding 5,500 patients to its addressable market in the U.S. and representing an additional $12.1 billion commercial opportunity at $2.2 million per treatment course. CRISPR Therapeutics is also expanding beyond gene editing through a partnership with Sirius Therapeutics to develop CTX611, a long-acting siRNA therapy designed to prevent dangerous blood clots with just two injections per year. The company's deep pipeline and partnership with a biotech giant position it to potentially expand its approved product portfolio and improve financial results by the end of the decade.
Intellia Therapeutics Stock Surges 38% in a Month on Pipeline Progress
Intellia Therapeutics shares have surged 38% over the past month, outperforming the industry, sector, and S&P 500, driven by positive regulatory and clinical milestones for its lead candidate lonvoguran ziclumeran. The phase III HAELO study evaluating lonvoguran ziclumeran for hereditary angioedema met its primary endpoint and a key secondary endpoint in April 2026, and additional data in June 2026 showed an 89% reduction in monthly attacks requiring on-demand treatment and a 91% reduction in moderate-to-severe attacks compared with placebo. Intellia initiated a rolling biologics license application submission to the FDA in April 2026 and plans a commercial launch in the first half of 2027 upon potential approval. The company is also advancing nexiguran ziclumeran in two late-stage studies for ATTR amyloidosis after the FDA lifted a clinical hold earlier this year. Despite a premium valuation of 3.79 times trailing book value versus the industry's 3.69, the Zacks Consensus Estimate for 2026 loss per share has narrowed from $3.46 to $3.18 over the past 60 days, and the 2027 loss estimate has narrowed from $1.01 to 65 cents. Zacks rates the stock a Hold, citing pipeline promise and narrowing losses but noting competition from CRISPR Therapeutics and Beam Therapeutics and the lack of marketed products.
New CRISPR 'DNA Shredder' Could Expand Gene-Editing Market
A newly discovered CRISPR-based tool that destroys diseased cells by shredding their DNA is generating excitement in scientific circles, with potential long-term implications for gene-editing companies like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics. Unlike traditional gene editing, this programmable cell-killing approach reads a signal unique to a diseased cell and cuts its DNA into fragments faster than the cell can repair, leading to cell death while sparing healthy cells. A May paper in Nature showed the therapy cutting lung cancer cell growth by about 50% in a lab dish, matching the chemotherapy drug cisplatin, and a June Nature paper extended the approach to target a gene mutated in 40% to 50% of all cancers. None of the major public CRISPR companies currently have this technology in their pipelines, though private German biotech Akribion Therapeutics is developing a program targeting HPV-positive head and neck cancer. The new papers significantly expand the addressable market for CRISPR-based medicine, and the incumbents may have an advantage due to their existing drug-delivery infrastructure.
CRISPR Therapeutics vs. Viking Therapeutics: Which Biotech Is a Better Buy in 2026?
CRISPR Therapeutics has launched Casgevy, the first FDA-approved CRISPR-based gene therapy, while Viking Therapeutics remains a clinical-stage company with no approved products. CRISPR reported fiscal 2025 revenue of about $3.5 million and a net loss of close to $581.6 million, with Casgevy priced at $2.2 million per patient per year in the U.S. and about 500 patients starting or about to start treatment. Viking generated no revenue in fiscal 2025 and posted a net loss of approximately $359.6 million, with its lead obesity candidate VK2735 in Phase III trials and Wall Street not expecting revenue until 2028. The analysis favors CRISPR because it has already reached the market, while Viking still faces regulatory risk in a crowded obesity drug field dominated by Eli Lilly and Novo Nordisk.
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics and Viking Therapeutics present contrasting investment profiles in the biotech sector. CRISPR reported fiscal 2025 revenue of approximately $3.5 million, a nearly 90% decline from the prior year, and a net loss of roughly $581.6 million, while Viking had no revenue and a net loss of approximately $359.6 million. CRISPR's current ratio stands at about 13.3 with a debt-to-equity ratio of roughly 0.2, whereas Viking's current ratio is close to 9.3 with essentially zero debt. On a forward earnings basis, Viking appears slightly more favorable with a forward P/E of 17.7 compared to CRISPR's 19.1, though both carry significant premiums. The analysis concludes that CRISPR, with its approved gene-editing treatment and modest sales, is a more investible choice than the pre-revenue Viking, despite both being highly speculative.
FDA approves Vertex's Casgevy for children as young as two with SCD and TDT
The FDA has approved Vertex Pharmaceuticals' gene therapy Casgevy for patients aged two years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. Casgevy becomes the first and only genetic therapy approved for children as young as two for both severe inherited blood disorders. The therapy was previously approved only for patients 12 years and older. Regulatory filings for the label expansion are under review in the United Kingdom and Saudi Arabia. Vertex leads global development and commercialization of Casgevy under a 2021 agreement with CRISPR Therapeutics, splitting costs and profits 60:40.
CRISPR Therapeutics has been one of the most searched-for stocks on Zacks.com recently, with shares gaining 4% over the past month while the broader market declined. The company is expected to post a loss of $1.13 per share for the current quarter, a 12.6% improvement from a year ago, though the consensus estimate has edged down 1.7% over the last 30 days. For the current fiscal year, the consensus loss estimate is $4.89 per share, a 24.4% improvement, while next fiscal year's estimate stands at a profit of $3.97 per share, up 18.9% from the prior year's expected figure. Revenue estimates show dramatic growth, with the current quarter's consensus at $7.42 million, a 733.3% year-over-year increase, and full-year estimates of $28.88 million and $131.2 million for the current and next fiscal years, respectively. CRISPR Therapeutics carries a Zacks Rank #3, suggesting it may perform in line with the broader market in the near term.
CRISPR Therapeutics and Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics AG and Vertex Pharmaceuticals present contrasting investment profiles for 2026, with Vertex offering a profitable, cash-generating cystic fibrosis franchise and CRISPR representing a high-risk, pure-play gene-editing bet. CRISPR's FY 2025 revenue fell roughly 90% to nearly $3.5 million, with a net loss of approximately $581.6 million, while Vertex generated close to $12 billion in revenue and net income of approximately $4.0 billion. CRISPR carries a low debt-to-equity ratio of roughly 0.2x and a current ratio of approximately 13.3x, but negative free cash flow of nearly $345.9 million, whereas Vertex posted strong free cash flow of nearly $3.2 billion with a debt-to-equity ratio of approximately 0.4x. Vertex trades at a forward P/E of 25.3x and a price-to-sales ratio of 10x, compared to CRISPR's forward P/E of 18.6x and price-to-sales ratio of 1270x. The two companies share profits from their joint gene-editing therapy CASGEVY on a 40% to 60% split, but CRISPR faces risks including a $600 million convertible note issuance in Q1 2026 and intellectual property litigation from ToolGen, while Vertex contends with revenue concentration in cystic fibrosis and clinical setbacks such as the RewinD-LB trial failure.
CRISPR Therapeutics, Insilico Medicine, and Compass Pathways Join Healthcare Technology and Innovation Index
The Healthcare Technology and Innovation index added three companies during its quarterly rebalance on June 19: CRISPR Therapeutics, Insilico Medicine, and Compass Pathways. CRISPR Therapeutics co-developed CASGEVY, the only viable gene-editing cure for sickle cell disease and beta-thalassemia, and is advancing therapies for cardiovascular and autoimmune diseases. Insilico Medicine is the first pure-play AI drug discovery company in the index, generating 6 to 8 preclinical candidates annually and projecting $1,287MM in FY 2026 revenue. Compass Pathways joined following final large-scale trials of COMP360, a synthetic psilocybin treatment that provided three to six months of relief for treatment-resistant depression.
The Motley Fool Names CRISPR Therapeutics, Zoetis, and Danaher as Top Stocks for a $1,000 Investment
The Motley Fool recommends CRISPR Therapeutics, Zoetis, and Danaher as the best healthcare stocks to buy with $1,000 right now. CRISPR Therapeutics is an emerging leader in genome editing with its first FDA-approved treatment, Casgevy, and analysts project sales to jump from $36 million to $145 million next fiscal year. Zoetis, a leading animal health company, has seen its stock hammered to 11 times 2026 earnings estimates—far below its decade-average P/E of 37—following controversy over its canine osteoarthritis drug Librela, though a class action lawsuit was dismissed. Danaher, a life sciences conglomerate that has returned over 30,000% in past decades, recently closed its $9.9 billion acquisition of Masimo and trades at about 21 times 2026 earnings estimates with expected annual earnings growth of 9%.
CRISPR Therapeutics Stock Swings as Market Weighs Commercial Progress Against Losses
CRISPR Therapeutics has experienced sharp stock swings over the past six months as investors assess its transition from a gene-editing pioneer to a commercial-stage biotech. The company reported just $1.46 million in revenue and a net loss of $122.9 million in the first quarter of 2026, despite the landmark approval of its sickle cell therapy CASGEVY in late 2023. Commercial adoption remains slow due to complex treatment procedures, though the number of authorized treatment centers is growing. CRISPR ended the quarter with approximately $2.4 billion in cash, cash equivalents, and marketable securities, providing flexibility to fund research. The market is also watching CTX112, an off-the-shelf CAR-T therapy for cancer, which could tap a market projected to grow from $5.8 billion in 2025 to over $22 billion by 2033, though it remains years from potential approval.
CRISPR Therapeutics and Vertex Pharmaceuticals Named Top Biotech Stocks for 2026
The Motley Fool highlights CRISPR Therapeutics and Vertex Pharmaceuticals as two of the best biotech stocks to buy in 2026, citing innovative pipelines and upcoming catalysts. CRISPR Therapeutics, a gene editing specialist, expects data readouts for its anticoagulant CTX611 and cholesterol therapy CTX310 in the second half of the year, while its Casgevy revenue is projected to ramp up. Vertex Pharmaceuticals, which holds a monopoly in cystic fibrosis, recently earned approval for Journavx and announced positive phase 3 results for povetacicept in IgA nephropathy, with a U.S. regulatory application completed and potential approval by year-end. The SPDR S&P Biotech ETF has gained 61% over the past 12 months, outperforming the S&P 500's 25% rise.